ASX Announcements
Application for quotation of securities - TLX
Appendix 2A (Application for Quotation of Securities)
- Sep 26, 2024
- 6 pages
Market Sensitive
Telix to Acquire RLS for US Manufacturing and Distribution
Asset Acquisition, Progress Report
- Sep 23, 2024
- 3 pages
Notification regarding unquoted securities - TLX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)
- Sep 11, 2024
- 7 pages
Application for quotation of securities - TLX
Appendix 2A (Application for Quotation of Securities)
- Sep 9, 2024
- 6 pages
September
Telix on $1b spending spree to build US radiopharmacy network
The biotech is investing heavily in global networks that will enable it to control the supply and distribution of nuclear medicines used to treat cancer.
- Michael Smith
The five pharma stocks exciting investors
Risky but with rewards, Australian pharmaceutical companies developing treatments for rare diseases are competing for investor attention.
- Michael Smith
July
Telix upsizes convertibles deal to $650m; delta block clears at $18.70
The pharmaceuticals company joins Xero and New Hope, which raised $1.27 billion and $300 million respectively in June via convertibles.
- Sarah Thompson, Kanika Sood and Emma Rapaport
JPMorgan shops $226m delta placement block for Telix notes deal
Terms sent to potential investors show Telix shares were being offered under a variable price book build at $18.60 a share to $19.60.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Telix shares hit new high on upgraded revenue forecast
The biotech’s shares double in value this year due to strong sales in the United States for its prostate cancer imaging product.
- Michael Smith
The ’10-bagger’ stocks that helped push the ASX above 8000
Two blockbuster biotech winners and beneficiaries of investment in the energy transition helped create wealth for savvy investors as shares topped 8000 points.
- Tom Richardson
June
Aussie high-flyer’s wings clipped by US investors
Red-hot biotech Telix got a shock when US investors wanted a chunky discount to buy stock. So it’s walking away looking silly, but with its pride intact.
- Anthony Macdonald
Telix pulls $300m Nasdaq IPO as investors demand deep discount
The cancer treatment hopeful had announced plans to list in New York only last week as it searched for more capital. On Friday, it withdrew from the initial public offering.
- Kylar Loussikian
Telix greenlights $300m Nasdaq listing in search for deep pockets
It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut overnight.
- Joshua Peach
April
Alium Capital preps first new fund in seven years
The Sydney investor is targeting wealth groups and superannuation funds for its new private and public equity fund.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Why picking ASX biotechs is mostly for the crazy brave
It’s a space with a reputation for rollercoaster returns and outlandish sales pitches, but some investors get lucky.
- Tom Richardson
January
- Opinion
- Chanticleer
Why $3b Aussie darling Telix needs to grow wings
If Telix wants to truly mix it with the big players, it needs to be closer to those that can fund it.
- Anthony Macdonald
June 2023
Aussie nuclear medicine firm breaks into EU amid huge growth
Melbourne-based Telix has opened a $21 million factory in Belgium which allows it to deliver to Europe, likely adding another leg to its already breakneck growth.
- Hans van Leeuwen
October 2022
The cash clues that suggest Dreamworld owner is wildly undervalued
Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢.
- Emma Rapaport
August 2022
China’s Grand Decade drops $73m Telix stake, JPM seeks buyers
JPMorgan’s equities desk is seeking buyers about a 3 per cent stake in ASX-listed Telix Pharmaceuticals on Thursday evening.
- Anthony Macdonald, Sarah Thompson and Kanika Sood
Tech rally gathers pace, Block, Atlassian earnings ahead
Shares closed flat as a tech sector rally was offset by falls among the miners. Afterpay-owner Block will report its June-quarter results on Friday morning.
- Tom Richardson
Fund managers back market darling Telix Pharmaceuticals
Healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.
- Tom Richardson
January 2022
All eyes on China Grand in Telix Pharma deal
One investor’s participation matters more than the others in Telix Pharma’s $175 million raise.
- Anthony Macdonald, Sarah Thompson and Kanika Sood
Telix Pharma bulks up with $175m raising, insider selldown
ASX-listed oncology company Telix Pharmaceuticals shares have gone into a trading halt as the group prepares to pitch investors for fresh funds.
- Anthony Macdonald, Sarah Thompson and Kanika Sood
November 2021
Telix gets first regulatory tick on prostate cancer imaging product
The Therapeutic Goods Administration has approved the biotech’s product Illuccix, helping to push its shares higher by over 8 per cent.
- Carrie LaFrenz